Clinical trials: Glabellar Lines
Facial Rhytides, Crow's Feet Lines
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides)
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines
- Trial name
- NCT01189760
- Testing
- onabotulinumtoxinA 24 U, onabotulinumtoxinA 44 U, normal saline
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 917 people
- Sponsor
- Allergan
Rhytids in the Glabellar Region
Efficacy Trial for the Reduction of Glabellar Lines
The purpose of this study is to evaluate the ability of the Serene RF System to effectively improve the appearance of dynamic glabellar lines and sustain the effect for a minimum of 3 months.
- Trial name
- NCT02466178
- Testing
- Serene RF System
- Where
- 5 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Serene Medical Inc
Glabellar Lines
MT10109L in the Treatment of Glabellar Lines
To evaluate the safety and efficacy of MT10109L in the treatment of glabellar lines (GL) in participants with moderate to severe GL.
- Trial name
- NCT03795922
- Testing
- MT10109L
- Where
- 15 sites in United States, Belgium and 1 more
- Volunteers
- 234 people
- Sponsor
- Medy-Tox
Glabellar Frown Lines
Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines
This is a blinded, randomized study in the US to compare the duration response of two different concentrations of BOTOX in healthy female subjects with moderate to severe dynamic glabellar lines on maximum frown.
- Trial name
- NCT05083286
- Testing
- OnabotulinumtoxinA
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Clinical Testing of Beverly Hills
Skin Aging
Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines
This study evaluates the patient satisfaction and onset of effect following treatment with botulinum toxin Type A in the treatment of glabellar rhytids (frown lines)
- Trial name
- NCT00856414
- Testing
- botulinum toxin Type A
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Allergan
Glabellar Frown Lines
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II
The aim of this study is to assess the efficacy and safety of BoNT/a-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.
- Trial name
- BLESS-II (NCT02677805)
- Testing
- Botulinum Toxin A, Botulinum Toxin A - Open Label
- Where
- 7 sites in United States
- Volunteers
- 251 people
- Sponsor
- Croma-Pharma GmbH
Glabellar Frown Lines
Safety and Efficacy Study of Dysport RU and Glabellar Lines
The primary objective is to assess the dose response versus placebo of a single treatment of Dysport RU (Dysport RU, Ready to Use, for injection), for the improvement in appearance of moderate to severe glabellar lines at maximum…
- Trial name
- NCT01333397
- Testing
- Botulinum toxin type A
- Where
- 8 sites in France, Germany
- Volunteers
- 176 people
- Sponsor
- Ipsen
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in…
- Trial name
- EV-006 (NCT02428608)
- Testing
- DWP-450 (Botulinum purified neurotoxin, Type A)
- Where
- United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Frown Lines
Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines
Efficacy and safety of ATGC-100 are assessed in subjects with moderate to severe glabellar lines.
- Trial name
- NCT04830345
- Testing
- ATGC-100 100U, Botox 100U
- Where
- South Korea
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Hyperhidrosis, Muscle Spasticity
Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea
This post marketing surveillance study in Korea will evaluate the safety and efficacy of BOTOX (botulinum toxin Type A) in patients who receive treatment according to standard of care for primary axillary hyperhidrosis, focal…
- Conditions
- Hyperhidrosis, Muscle Spasticity, Glabellar Lines
- Trial name
- NCT02043145
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 727 people
- Sponsor
- Allergan
Glabellar Frown Lines
Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines
This is a Phase 2a open-label, single-arm study to evaluate the effects of DaxibotulinumtoxinA-lanm (DAXI) for Injection on the treatment of dynamic forehead lines (FHL) and glabellar lines (GL).
- Trial name
- NCT06411002
- Testing
- DAXXIFY
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Frown Lines
Treatment of Moderate to Severe Glabellar Lines
The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe GL.
- Trial name
- READY-1 (NCT04249583)
- Testing
- botulinum toxin
- Where
- 14 sites in United States, Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Lines
The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines
A Phase I/Ⅱ Clinical Trial to Compare the Safety and Efficacy of HU-014 versus Botox® in Subject with Moderate to Severe Glabellar Lines
- Trial name
- NCT02961673
- Testing
- HU-014 Inj, Botox Inj
- Where
- South Korea
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Glabellar Lines
To Evaluate HU-045 With Moderate to Severe Glabellar Lines
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
- Trial name
- NCT07870694
- Testing
- HU-045, Xeomin®
- Where
- South Korea
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- Huons Biopharma
Glabellar Lines
Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines
This is Multicenter, Randomized, Double-blind, Placebo-controlled, Single-dose Study to evaluate Safety and Efficacy of JTM201 in patients with Moderate or Severe Glabellar Lines
- Trial name
- NCT06246552
- Testing
- JTM201
- Where
- United States
- Volunteers
- 480 people
- Sponsor
- Jetema USA Inc.
Glabellar Frown Lines
The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines
To Confirm the non-inferiority of CUNOX® to BOTOX® in the glabellar line improvement of moderate to severe glabellar lines.
- Trial name
- NCT03837561
- Testing
- Cunox, Botox
- Where
- Russia
- Volunteers
- 136 people
- Sponsor
- Medy-Tox
Glabellar Lines
A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT07756580
- Testing
- AGN-151586, BOTOX
- Where
- 8 sites in United States
- Volunteers
- 120 people
- Sponsor
- AbbVie